Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

Umberto Gianelli, Alessandra Iurlo, Daniele Cattaneo, Giorgio Lambertenghi-Deliliers

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.

Original languageEnglish
Pages (from-to)255-264
Number of pages10
JournalExpert Review of Hematology
Volume7
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Philadelphia Chromosome
Neoplasms
Phenotype
Mutation
Pathologists

Keywords

  • Bone marrow
  • essential thrombocythemia
  • megakaryocyte
  • myelofibrosis
  • myeloproliferative neoplasms
  • polycythemia vera
  • primary myelofibrosis

ASJC Scopus subject areas

  • Hematology

Cite this

Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. / Gianelli, Umberto; Iurlo, Alessandra; Cattaneo, Daniele; Lambertenghi-Deliliers, Giorgio.

In: Expert Review of Hematology, Vol. 7, No. 2, 2014, p. 255-264.

Research output: Contribution to journalArticle

@article{29a18f0fe8df4eefb25fb329d716a475,
title = "Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms",
abstract = "As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15{\%} of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.",
keywords = "Bone marrow, essential thrombocythemia, megakaryocyte, myelofibrosis, myeloproliferative neoplasms, polycythemia vera, primary myelofibrosis",
author = "Umberto Gianelli and Alessandra Iurlo and Daniele Cattaneo and Giorgio Lambertenghi-Deliliers",
year = "2014",
doi = "10.1586/17474086.2014.876898",
language = "English",
volume = "7",
pages = "255--264",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

AU - Gianelli, Umberto

AU - Iurlo, Alessandra

AU - Cattaneo, Daniele

AU - Lambertenghi-Deliliers, Giorgio

PY - 2014

Y1 - 2014

N2 - As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.

AB - As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.

KW - Bone marrow

KW - essential thrombocythemia

KW - megakaryocyte

KW - myelofibrosis

KW - myeloproliferative neoplasms

KW - polycythemia vera

KW - primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84896368819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896368819&partnerID=8YFLogxK

U2 - 10.1586/17474086.2014.876898

DO - 10.1586/17474086.2014.876898

M3 - Article

C2 - 24524231

AN - SCOPUS:84896368819

VL - 7

SP - 255

EP - 264

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -